Pharma News

Roche announced the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully integrated into Roche Diagnostics.

Antibiotic-resistant bacteria have become a rapidly growing threat to public health. Each year, they account for more than 2.8 million infections, according to the U.S. Centers for Disease Control and Prevention. Without new antibiotics, even common injuries and infections harbor the potential to become lethal.

Mayo Clinic researchers mapped how the measles virus mutated and spread in the brain of a person who succumbed to a rare, lethal brain disease. New cases of this disease, which is a complication of the measles virus, may occur as measles reemerges among the unvaccinated, say researchers.

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc, a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition.

Bristol Myers Squibb and RayzeBio, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for USD 62.50 per share in cash, for a total equity value of approximately 4.1 billion USD, or 3.6 billion USD net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.

Blood fat-lowering statins could slow the progression of Alzheimer's disease, at least for some patients. This is the result of a new study led by Karolinska Institutet published in Alzheimer Research and Therapy. But the researchers are cautious in their interpretations and see the results as a first step in a research journey that may eventually provide the answer.

Down syndrome, a congenital disorder stemming from abnormal cell division and differentiation, is most common in newborns fated to neurodevelopmental delays and other health complications.

A recent study by researchers at the Hebrew University-Hadassah Medical School, Bar-Ilan University and Vanderbilt University has developed a new paradigm for early stages of type 1 diabetes (T1D), suggesting a new etiology that does not involve viral infection.

The genetic alphabet contains just four letters, referring to the four nucleotides, the biochemical building blocks that comprise all DNA. Scientists have long wondered whether it’s possible to add more letters to this alphabet by creating brand-new nucleotides in the lab, but the utility of this innovation depends on whether or not cells can actually recognize and use artificial nucleotides to make proteins.